However, the genomic heterogeneity in ctDNA during treatments and its impact on clinical outcomes remain largely unknown. Design We conducted a prospective cohort study (NCT04228614) of 171 patients ...

Get Instant Summarized Text (Gist) The FDA has approved Enhertu for treating adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow breast cancer. This approval follows the ...

Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for the treatment of patients with microsatellite stable metastatic colorectal ...

1Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. *Corresponding Author: John Paul Shen, Department of Colon and Rectal Surgery, The ...

Adenomatous polyps typically do not cause symptoms unless they progress to colon cancer. Even then, there may be no sign of a problem until the malignancy is advanced. This is why colon cancer ...

He is a native English speaker. A blood test that accurately detects colon cancer in middle-aged and older people and also rules it out when it is not present can help to increase the rate of ...

The CONVERGE study evaluates NBTXR3's efficacy in stage III unresectable NSCLC with standard chemoradiation and durvalumab. NBTXR3, a hafnium oxide nanoparticle, is activated by radiotherapy to induce ...

Nancy Leftenant-Colon, who battled racial discrimination in a barrier-breaking career as a military nurse, serving as the first African American in the regular Army Nurse Corps and later caring ...

Should the primary tumor, if asymptomatic, be resected in patients with colon cancer with synchronous unresectable metastases? Study results hint that the answer is no. FOLFOXIRI plus panitumumab ...

Toxicology and clinical protocol development of DUO-207: An ultrasmall nanomedicine co-delivering gemcitabine and paclitaxel for the treatment of metastatic pancreatic cancer. This is an ASCO Meeting ...

A multicenter, prospective observational study of chemotherapy in elderly patients with biliary tract cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium.

Dr. Kim’s clinical and research interests focus on gastrointestinal tumors, in particular hepatobiliary and colon cancer. He is a principal investigator in multiple investigator-initiated and ...